Angiex’s AGX101 Phase I Study Receives Critical Support from Abzena
Angiex has made significant strides in its Phase I study of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to treat aggressive cancers by targeting tumor blood vessels. Abzena, a leading biopharmaceutical services provider, plays an essential role in supporting the trial by supplying the critical clinical trial materials necessary to advance this innovative therapy.
Clinical Research News recently covered the collaboration, highlighting how Abzena’s expertise in cGMP manufacturing has enabled Angiex to progress AGX101 through clinical development. As a leading outlet for news on clinical trials and research innovation, Clinical Research News emphasizes the importance of partnerships like that between Angiex and Abzena in accelerating the development of novel cancer treatments. Their coverage underscores the growing promise of ADC therapies in addressing unmet needs in oncology.